Sedodex® effect on blood gases in surgery

The effect of Sedodex® on ventilation efficacy in patients undergoing one lung ventilation during thracic surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017012116077N8

Enrollment

Registered

2017-01-27

Start date

2017-02-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug effect on lung ventilation. Intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classified

Interventions

Intervention 1: Study group: 1 microgram per kilogram body weight, Sedodex® will be given during first 10 minutes after anesthesia and infusion will be administered in dosage of 0.9 microgram per kilo

Treatment - Drugs

Placebo

Study group: 1 microgram per kilogram body weight, Sedodex® will be given during first 10 minutes after anesthesia and infusion will be administered in dosage of 0.9 microgram per kilogram body weight

control group: 1 microgram per kilogram body weight, placebo (normal saline serum) will be given during first 10 minutes after anesthesia and infusion will be administered in dosage of 0.9 microgram p

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: adult patients aged between 18 to 65 year-old; patients candidate to undergo elective thoracotomy with one lung ventilation; class I or III according to ASA classification. Exclusion criteria: severe cardiac disease; severe hepatic disease; severe renal disease; body mass index greater than 30; previous history of thoracic surgery; anemia (hemoglobin less than 12mg / dl ); chest trauma; patients suffering intraoperative complications.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Evaluating sedodex effects on arterial blood oxygenation level. Timepoint: before anesthesia, 10 minutes after anesthesia and 20 minutes before end of the operation. Method of measurement: arterial blood gas sampling.;Evaluating sedodex effects on arterial blood carbon dioxide level. Timepoint: before anesthesia, 10 minutes after anesthesia and 20 minutes before end of the operation. Method of measurement: arterial blood gas sampling.;Evaluating sedodex effects on arterial blood pH level. Timepoint: before anesthesia, 10 minutes after anesthesia and 20 minutes before end of the operation. Method of measurement: arterial blood gas sampling.	—

Measure

Time frame

Evaluating sedodex effects on arterial blood oxygenation level. Timepoint: before anesthesia, 10 minutes after anesthesia and 20 minutes before end of the operation. Method of measurement: arterial blood gas sampling.;Evaluating sedodex effects on arterial blood carbon dioxide level. Timepoint: before anesthesia, 10 minutes after anesthesia and 20 minutes before end of the operation. Method of measurement: arterial blood gas sampling.;Evaluating sedodex effects on arterial blood pH level. Timepoint: before anesthesia, 10 minutes after anesthesia and 20 minutes before end of the operation. Method of measurement: arterial blood gas sampling.

—

Secondary

Measure	Time frame
Measurement the use of other anesthetic agents during dexmetedomidine administration. Timepoint: after operation. Method of measurement: measuring dosage of anesthetic agents administered other than sedodex.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Ziaeddin Rasihashemi

Tabriz University of Medical Sciences

ramouza@tbzmed.ac.r+98 41 3441 3895

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026